Cargando…

Expression of TRPM8 in human reactive lymphoid tissues and mature B-cell neoplasms

Transient receptor potential melastatin 8 (TRPM8) is a member of the transient receptor potential superfamily of Ca(2+) channels. The aim of the present study was to clarify TRPM8 expression in reactive lymphoid tissues and mature B-cell neoplasms. Reactive and neoplastic lymphoid tissues were used...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirai, Akinori, Aung, Naing Ye, Ohe, Rintaro, Nishida, Akiko, Kato, Tomoya, Meng, Hongxue, Ishizawa, Kenichi, Fujii, Junichi, Yamakawa, Mitsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176370/
https://www.ncbi.nlm.nih.gov/pubmed/30344743
http://dx.doi.org/10.3892/ol.2018.9386
Descripción
Sumario:Transient receptor potential melastatin 8 (TRPM8) is a member of the transient receptor potential superfamily of Ca(2+) channels. The aim of the present study was to clarify TRPM8 expression in reactive lymphoid tissues and mature B-cell neoplasms. Reactive and neoplastic lymphoid tissues were used to evaluate TRPM8 expression by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). TRPM8(+) cells were frequently detected in the follicular light zone and marginal zone of reactive lymphoid tissues. Double immunostaining revealed that TRPM8(+) cells co-expressed cluster of differentiation (CD) 38, CD79a, CD138, interferon regulatory factor 4/melanoma associated antigen (mutated) 1, B cell CLL/lymphoma 6 and transmembrane activator and CAML interactor. TRPM8(+) neoplastic cells were frequently detected in plasma cell myeloma. The positive band of TRPM8 mRNA was confirmed by RT-PCR in cases of myeloma. The present study is, to the best of our knowledge, the first to demonstrate the expression of TRPM8 in reactive lymphoid tissues and mature B-cell neoplasms, revealing that TRPM8 is frequently expressed in pre-plasmablasts, plasmablasts, plasma cells and mature B-cell lymphomas that are likely to differentiate into plasma cells.